Liedtke M, Pandey P, Kumar S, Kharbanda S, Kufe D
Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Oncogene. 1998 Oct 15;17(15):1889-92. doi: 10.1038/sj.onc.1202117.
The oncogenic Bcr-Abl variant of the c-Abl tyrosine kinase transforms cells by a mechanism dependent on activation of the stress-activated protein kinase (SAPK). Other work has shown that c-Abl interacts with the SHPTP1 protein tyrosine phosphatase in induction of SAPK activity by genotoxic stress. The present studies demonstrate that Bcr-Abl binds constitutively to SHPTP1. We show that Bcr-Abl phosphorylates SHPTP1 on C-terminal Y536 and Y564 sites. The functional significance of the Bcr-Abl/SHPTP1 interaction is supported by the finding that SHPTP1 regulates Bcr-Abl-induced SAPK activity. Importantly, SHPTP1 also decreases Bcr-Abl-dependent transformation of fibroblasts. These findings indicate that SHPTP1 functions as a tumor suppressor in cells transformed by Bcr-Abl.
c-Abl酪氨酸激酶的致癌性Bcr-Abl变体通过一种依赖于应激激活蛋白激酶(SAPK)激活的机制使细胞发生转化。其他研究表明,在基因毒性应激诱导SAPK活性的过程中,c-Abl与SHPTP1蛋白酪氨酸磷酸酶相互作用。本研究证明Bcr-Abl与SHPTP1持续结合。我们发现Bcr-Abl使SHPTP1的C末端Y536和Y564位点发生磷酸化。SHPTP1调节Bcr-Abl诱导的SAPK活性这一发现支持了Bcr-Abl/SHPTP1相互作用的功能意义。重要的是,SHPTP1还可降低Bcr-Abl依赖的成纤维细胞转化。这些发现表明,SHPTP1在由Bcr-Abl转化的细胞中起肿瘤抑制作用。